Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

About

Brief Summary

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)

Study Type

Observational

Phase

N/A

Eligibility

Gender

All

Minimum Age

18 Years

Maximum Age

N/A

Inclusion Criteria:

Histologically confirmed PanNEN. a. The diagnostic biopsy may have been taken from any site (primary or metastatic).
New and existing PanNEN participants will be eligible (any grade, any stage, any age > 18 years).
Participants willing and able to comply with the study procedures.

Exclusion Criteria:

Inability to provide informed consent.
For participants who have not had prior testing with a dedicated germline pane of at least 80 genes:
- Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic).
- Active hematologic malignancy.
- History of allogenic bone marrow transplant or stem cell transplant.

Not a fit? Find another study